Telix Pharmaceuticals reports 18% QoQ revenue growth in 1Q24, reaffirms 2024 revenue growth guidance of 35-40% YoY increase, and targets to launch three new products in the U.S. this year.
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.